GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. Neurofibromatosis Type 1 (NF1), a genetic condition where tumors grow on the nerves and skin, is the focus of a pre-clinical stage program in GondolaBio’s portfolio. NF1 affects multiple organ systems, with a wide range of manifestations ranging from neurofibromas (benign nerve sheath tumors) that carry the risk of malignant transformation, to learning difficulties and bone abnormalities. Despite having two FDA-approved MEK inhibitors for NF1 patients, there is still a huge unmet need in providing safer and more efficacious treatment options to the NF1 patients, and GondolaBio strives to address this gap. To learn more, visit us at gondolabio.com
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Associate degree